TNFRSF1B and neoplasm: To explore whether the cured tumor-free mice acquired 4T1-specific immunity, the two mice reached CR after anti-TNFR2 treatment was subcutaneously injected with either 4T1 or CT26 tumor cells on contralateral flanks, and the tumor formation of both flanks was monitored twice per week.